预约演示
更新于：2025-05-24
Recombinant human thrombopoietin(Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.)
重组人血小板生成因子 (上海三生国健)
更新于：2025-05-24
概要
基本信息
药物类型 集落刺激因子 |
别名- |
作用方式 激动剂 |
作用机制 TPO receptor激动剂(血小板生成素受体激动剂) |
治疗领域 |
在研适应症- |
非在研适应症 |
原研机构 |
在研机构- |
非在研机构 |
权益机构- |
最高研发阶段无进展临床1期 |
首次获批日期- |
最高研发阶段(中国)无进展 |
特殊审评- |
登录后查看时间轴
关联
8
项与 重组人血小板生成因子 (上海三生国健) 相关的临床试验ChiCTR2400081344
Clinical study on the efficacy and safety of recombinant human thrombopoietin in the prevention and treatment of thrombocytopenia after chemotherapy for lymphoma
ChiCTR2100049137
A single-center, prospective, self-controlled study of recombinat human thrombopoietin in the treatment of thrombocytopenia following high dose cytarabine consolidation chemotherapy in acute myeloid leukemia
ChiCTR1900027735
Clinical study for high-dose dexamethasone combined with versus without human recombinant thrombopoietin (rhTPO) in the treatment of newly diagnosed primary immune thrombocytopenia (ITP)
100 项与 重组人血小板生成因子 (上海三生国健) 相关的临床结果
登录后查看更多信息
100 项与 重组人血小板生成因子 (上海三生国健) 相关的转化医学
登录后查看更多信息
100 项与 重组人血小板生成因子 (上海三生国健) 相关的专利（医药）
登录后查看更多信息
4
项与 重组人血小板生成因子 (上海三生国健) 相关的文献（医药）2018-06-01Haematologica
Comment to the article by Arai Y, Jo T, Matsui H, Kondo T and Takaori-Kondo A: “Comparison of up-front treatments for newly diagnosed immune thrombocytopenia – a systematic review and network meta-analysis”. Haematologica 2018;103(1):163–171. Need to direct immune thrombocytopenia therapy towards shared goals
Letter
作者: Cirasino, Lorenzo ; Semeraro, Stefano
A polemic in response to Arai et. al., (Haematologica 2018;103(1):163-171) is given.Arai et. al. reported the results of a systematic review and network meta-anal. comparing the efficacy and safety of different treatments utilized in adults for primary newly diagnosed immune thrombocytopenia.On the basis of the results of their recent work Arai et. al. sustains that human thrombopoietin agonists may be beneficial up-front therapies in addition to conventional corticosteroid monotherapy in adults with primary immune thrombocytopenia.The study found that the main outcome, represented by a sustained response, was achieved by a significantly higher proportion of patients treated with recombinant human thrombopoietin agonists plus dexamethasone or rituximab plus dexamethasone therapy.The author states that these conclusions did not take into consideration the need for a preliminary agreement on the goals that define the treatments foreseen for the different sequences of disease of primary immune thrombocytopenia in adults, the so-called lines of therapy.This is particularly true for second-line treatment, given the discordant suggestions for this line of therapy between the two most influential guidelines on the treatment of the disease.The author concluded that this study requires a preliminary agreement on the goal of this line of therapy, as sustained for other lines of immune thrombocytopenia therapy.
Frontiers in pharmacology
Case Report: Severe thrombocytopenia induced by adalimumab in rheumatoid arthritis: A case report and literature review
作者: Yu, Limei ; Zeng, Yu ; Yuan, Tian ; Pu, Tao ; Hong, Qifu ; Liao, Tiantian ; Li, Mengqing ; Yu, Qiong ; Yu, Dan
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by persistent joint inflammation. In recent decades, biological agents such as anti-tumor necrosis factor-α (TNF-α) drugs have been applied in the treatment of RA and it achieved great improvement. The treatment has its side effects, but severe thrombocytopenia is very rare. In this case report we described the occurrence of severe thrombocytopenia in a patient with RA who was treated with adalimumab. Specially, the symptoms of the RA are not significantly improved by adalimumab treatment and severe thrombocytopenia it induced is resistant to treatment. After receiving four doses of adalimumab, the patient’s platelet count dropped to 4 × 103/μl. We halted adalimumab and administered glucocorticoids, interleukins, and platelet transfusion. On the sixth day, the platelet count rose to 52 × 103/μl. Lab tests and bone marrow pictures were unremarkable. Patient was treated with prednisone for maintenance. On day 17, the platelet count declined to 12 × 103/μl. We started the patient on methylprednisolone and recombinant human thrombopoietin (rh-TPO), but the effect was not significant. On day 25, intravenous immune globulin (IVIG) was applied in place of the rh-TPO. On 29th day, the patient’s platelets returned to normal. We summarized the existing literature on thrombocytopenia induced by anti-TNF-α drugs. This case suggested immunoglobulins could be considered for the treatment of refractory thrombocytopenia.
Frontiers in Pharmacology
Clinical efficacy of avatrombopag and recombinant human thrombopoietin in the treatment of chronic liver disease-associated severe thrombocytopenia: A real-world study
Article
作者: Yao, Huan-Zhang ; Nashan, Bjoern ; Meng, Fan-Zheng ; Liu, Lian-Xin ; Li, Lei ; Wang, Wei ; Shen, Ai-Zong ; Song, Rui-Peng ; Wang, Yong-Shuai ; Song, Hua-Chuan ; Zhang, Sai ; Wang, Ji-Zhou ; Zhang, Shen-Yu
Purpose: To investigate the clinical efficacy of avatrombopag, an oral thrombopoietin receptor agonist, versus subcutaneous recombinant human thrombopoietin (rh-TPO) in the treatment of severe thrombocytopenia (TCP) associated with chronic liver disease (CLD).Methods: Clinical data of 250 patients with severe TCP associated with CLD were collected in a single hospital from January 2019 to January 2022. The main parameters measured were the therapeutic response rate, changes in platelets (PLTs), and adverse events. Propensity score matching (PSM) was used to avoid possible selection bias.Results: After PSM, a total of 154 patients were enrolled in the study: 77 in the avatrombopag group and 77 in the rh-TPO group. There was no statistically significant difference between the two groups in the effect of increasing the PLT count (Waldχ2 = 1.659, p = 0.198; Waldχ2 = 0.220, p = 0.639). In addition, no interaction between time and different medications was found (Waldχ2 = 0.540, p = 0.910; Waldχ2 = 1.273, p = 0.736). Interestingly, in the subgroup analysis, both before and after PSM, avatrombopag showed better clinical efficacy than rh-TPO in the treatment of TCP associated with CLD in Child‒Pugh Class A (88.89% vs. 63.41%, p =0.003; 81.33% vs. 61.76%, p = 0.043). Fewer patients reported dizziness in the avatrombopag group than in the rh-TPO group both before and after PSM (7.8% vs. 25.0%; 7.8% vs. 24.7%, p < 0.05).Conclusion: Both before and after PSM, avatrombopag showed better clinical efficacy than rh-TPO in the treatment of TCP associated with CLD in Child‒Pugh Class A and showed a lower incidence of dizziness in all patients.
100 项与 重组人血小板生成因子 (上海三生国健) 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 血小板减少症 | 临床1期 | 中国 | 2017-08-24 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 20 | 膚築壓築憲憲淵網範膚(糧鏇觸糧餘範構獵蓋壓) = 鏇鏇襯積鏇獵壓觸醖餘 齋願構淵鬱選鏇範襯鹽 (觸顧觸網糧襯願選淵壓 ) | - | 2023-06-08 | |||
N/A | - | 29 | 鹽鏇願鬱艱糧壓鹹廠壓(壓餘糧糧壓構鹹顧艱顧) = rhTPO was well tolerated in all patients without side effects urging withdrawal and clinical intervention 鏇衊選築鑰鏇淵遞製鏇 (築鬱艱醖夢餘壓蓋廠醖 ) | - | 2022-03-19 | ||
N/A | 255 | (Low CD34+ stem cells without rhTPO) | 鏇獵顧製選夢窪獵範積(製窪顧鏇鏇壓鑰獵餘築) = 壓選餘願繭餘簾鬱廠壓 衊夢顧鏇醖夢選築構願 (簾衊餘鹹蓋餘獵範繭鑰 ) 更多 | 积极 | 2020-05-14 | ||
(Normal CD34+ stem cells without rhTPO) | 鏇獵顧製選夢窪獵範積(製窪顧鏇鏇壓鑰獵餘築) = 願觸構選壓壓範糧壓齋 衊夢顧鏇醖夢選築構願 (簾衊餘鹹蓋餘獵範繭鑰 ) | ||||||
N/A | - | 59 | 鹹繭繭繭壓齋構獵鬱遞(醖憲淵觸鬱夢齋膚糧網) = 艱襯襯鬱鏇選夢構夢製 齋範餘範鬱積觸簾鏇網 (衊襯襯艱鏇膚簾鬱淵顧, (10 ~ 12)) 更多 | - | 2019-05-16 | ||
(untreated group) | 鹹繭繭繭壓齋構獵鬱遞(醖憲淵觸鬱夢齋膚糧網) = 鏇築範簾構繭壓夢製選 齋範餘範鬱積觸簾鏇網 (衊襯襯艱鏇膚簾鬱淵顧, (9 ~ 11)) 更多 | ||||||
N/A | 24 | (Prophylactic treated cycle) | 簾壓襯夢範膚齋淵襯獵(廠齋獵觸醖蓋築窪獵憲) = 網積廠廠餘築夢觸鏇膚 壓鬱網淵餘築製艱鬱觸 (築觸醖積製構鏇齋齋齋, ± 2) 更多 | - | 2010-05-20 | ||
(Control cycle) | 簾壓襯夢範膚齋淵襯獵(廠齋獵觸醖蓋築窪獵憲) = 膚壓製選遞獵憲選築願 壓鬱網淵餘築製艱鬱觸 (築觸醖積製構鏇齋齋齋, ± 3) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用